Active Ingredient(s):Tagraxofusp-erzs FDA Approved: * December 21, 2018 Pharm Company: *STEMLINE THERAPEEUTICS INC
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018, and after a second review, in the EU in January 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Tagraxofusp is a fusion protein consisting of i...
* May have multiple approval dates, manufacturers, or labelers.